Oct 27 (Reuters) - The European Medicines Agency (EMA) on Friday said available evidence does not support a causal association between GLP-1 receptor agonist drugs, which include Novo Nordisk's weight loss treatment Wegovy, and thyroid cancer. (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Varun H K)